SCHEMBL3325091

SCHEMBL3325091

NS(=O)(=O)c1ccc(C(=O)NCCN2CCCC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
NPSR1 Q6W5P4 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
CA12 O43570 3/20 0.63
CA9 Q16790 3/20 0.63
ACHE P22303 1/20 0.62
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
KDM4E B2RXH2 2/20 0.61
POLB P06746 2/20 0.60
CA2 P00918 7/20 0.59
CA1 P00915 6/20 0.59
CA14 Q9ULX7 1/20 0.58
GLA P06280 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322319 0.99 CYP1A2 (0.67) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL3326207 0.92 CA2 (0.61) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL3324311 0.91 ALDH1A1 (0.61) ALDH1A1CYP1A2CYP2D6CYP2C9CA12
SCHEMBL3330933 0.88 CD274 (0.68) ALDH1A1CYP1A2CYP2D6CA12CA9
SCHEMBL3408343 0.82 ALDH1A1 (0.71) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL30969330 0.82 ALDH1A1 (0.71) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL29605727 0.81 CYP1A2 (0.74) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL3401326 0.81 CYP1A2 (0.74) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL3324927 0.81 TSHR (0.70) ALDH1A1NPSR1CYP2D6CYP2C9CA12
SCHEMBL279945 0.80 NPSR1 (0.97) ALDH1A1NPSR1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
CN-101663267-A Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use UNIMED PHARMA SPOL SRO 2010-03-03 CN claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP disclosed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed
CN-101663267-A Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use UNIMED PHARMA SPOL SRO 2010-03-03 CN disclosed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP disclosed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 ALDH1A1 967/4885NPSR1 75/4885CYP1A2 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.